Risk of Dementia in Parkinson's Disease: A Systematic Review and Meta‐Analysis

Documenti analoghi

• Effects of Montelukast on Neuroinflammation in Parkinson's Disease: An Open Label Safety and Tolerability Trial with CSF Markers and [11C]PBR28 PET
  di: Johan Wallin, et al.
  Pubblicazione: (2025)
• Cortical Effects of Dopamine Replacement Account for Clinical Response Variability in Parkinson's Disease
  di: Alex I. Wiesman, et al.
  Pubblicazione: (2025)
• Association of Baseline Depression and Anxiety with Longitudinal Health Outcomes in Parkinson's Disease
  di: Yiwen Shi, et al.
  Pubblicazione: (2024)
• Subjective Cognitive Complaints in Parkinson's Disease: A Systematic Review and Meta‐Analysis
  di: Mattia Siciliano, et al.
  Pubblicazione: (2024)
• The FDA Has Ended Required Blood Monitoring for Clozapine Use—Will This Impact the Management of Parkinson's Disease Psychosis?
  di: Daniel Weintraub, et al.
  Pubblicazione: (2025)